This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Ionis Pharmaceuticals’s 8K filing here.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- What a Trump Win Looks Like for The Market Now and Into 2025
- NYSE Stocks Give Investors a Variety of Quality Options
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- The 3 Best Blue-Chip Stocks to Buy Now
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
